We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

A Solution for Pollen Allergies?

A Solution for Pollen Allergies? content piece image
Credit: Pixabay
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Birch pollen allergic rhinitis is the most common chronic disorder in the Northern part of the globe, and it attributes to significant morbidity and economic burden.

According to the new study by researchers at the University of Helsinki, pollen allergen immunotherapy has favorable effects on the molecular events and microbiome profile in the nasal membrane.

The researchers studied five healthy, nonsmoking adult subjects and six allergic rhinitis patients longitudinally during two springs and two winters in 2011 and 2012. Half of the allergy patients started subcutaneous birch allergen immunotherapy after the first winter.

In total, 44 nasal brushings were subjected to RNA-sequencing analysis to find gene expression and microbial community changes driven by allergic rhinitis and allergen immunotherapy.

According to the results, the group who started allergen immunotherapy showed decreased symptom score and reprogramming of nasal epithelial transcriptome, set of RNA molecules, during the pollen season.

"The immunotherapy affected asthma-, chemokine signaling-, and toll like receptor signaling pathways in the spring. No major differential expression was found between the two winters in any group," says researcher Sanna Toppila-Salmi from the University of Helsinki and Helsinki University Hospital.

The results also indicated that microbial community diversity of the group that underwent allergen immunotherapy approached that of the healthy controls.

According to the researchers, the study shows that RNA sequencing is a promising method to monitor allergen immunotherapy response.

This article has been republished from materials provided by the University of Helsinki. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference: Hanif et al. 2019. Birch pollen allergen immunotherapy reprograms nasal epithelial transcriptome and recovers microbial diversity. The Journal of Allergy and Clinical Immunology. DOI: https://doi.org/10.1016/j.jaci.2019.02.002.